Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Medicra (Journal of Medical Laboratory Science/Technology)
Novitasari, Fia
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Phytochemical Screening of White Turi (Sesbania grandiflora (L.) Pers.) Leaves Extract in Various Extraction Methods: Skrining Fitokimia Ekstrak Daun Turi Putih (Sesbania Grandiflora (L.) Pers.) pada Variasi Metode Ekstraksi Rohmah, Jamilatur; Saidi, Ida Agustini; Rofidah, Luthfiyah; Novitasari, Fia; Margareta, Frida Amelia
Medicra (Journal of Medical Laboratory Science/Technology) Vol. 4 No. 1 (2021): July
Publisher : Universitas Muhammadiyah Sidoarjo

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21070/medicra.v4i1.1395

Abstract

One of the Fabaceae family that has potential as medicinal plant is the white Turi plant (Sesbania grandiflora (L.) Pers.).The purpose of this study was to determine the content of secondary metabolites which can be extracted using a various extraction methods.The extraction method used are digestion, percolation, reflux, soxhlet, infusion, and decoction extraction. The Turi plants used come from Mojosari, Mojokerto.The results of the initial phytochemical screening of white Turi leaf extract (Sesbania grandiflora (L.) Pers.) Were extracts in six extraction methods containing alkaloids, saponins and tannins.In extracts using the digestion, soxhlet, and reflux method containing steroids.Meanwhile, the four extracts from the digestion, percolation, soxhlet, and reflux methods contain phenolic.And the infusion and decoction method extracts containing flavonoids and triterpenoids. The similarity of the phytochemical test results for each extract but with different intensity results.
Ivabradine in Heart Failure with Reduced Ejection Fraction (HFrEF): A Narrative Review of Clinical Outcomes Hidayaturahmah, Rizky; Khoerunisa, Erin; Suprahman, Nisa Yulianti; Novitasari, Fia
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 16, No 1
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.88590

Abstract

Background: Therapy for heart failure with reduced ejection fraction (HFrEF) patients is complex, involving several combinations of treatments, but there are still some problems, such as rehospitalization, reduced ejection fraction values, increased heart rate, and decreased quality of life. Ivabradine, a selective heart rate-lowering agent, offers adjunctive therapeutic benefits.Objective: This study aims to determine the characteristics of HFrEF patients who received additional therapy with ivabradine and to determine how ivabradine affects their clinical outcomes.Methods: This narrative review searched articles on PubMed, Cochrane Library, Google Scholar, and ScienceDirect. The research was limited to randomized controlled trial articles, observational studies, and cohorts with international and national English and/or Indonesian articles published in the last 10 years.Results: Twenty-eight studies (n=36,765) met the problem formulation and inclusion criteria were analyzed. Patients receiving ivabradine were predominantly male (74.9%), aged 56-65 years (81.9%), and had a history of smoking. Most patients had heart rate ≥70 bpm (75.4%), LVEF ≤30% (55.3%), BMI ≥28 kg/m² (87.1%), and NYHA class II-III (85.5%). The addition of ivabradine to the clinical outcome of HFrEF patients reduces heart rate (15.7 bpm), blood pressure (SBP: -4.4 mmHg; DBP: -0.9 mmHg), rehospitalization, and mortality, while improving LVEF and stroke volume, and quality of life. Adverse effects included manageable bradycardia and transient visual disturbances.Conclusion: Ivabradine effectively improves clinical outcomes in HFrEF patients as adjunct therapy, with significant benefits in cardiac function, symptom control, and prognosis.
Co-Authors Hidayaturahmah, Rizky Ida Agustini Saidi Jamilatur Rohmah Khoerunisa, Erin Margareta, Frida Amelia Nisa Yulianti Suprahman Rofidah, Luthfiyah